Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy

Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy

HC Wainwright upgrades Shattuck Labs on confidence in SL-325, a DR3 antibody aiming for stronger, durable IBD treatment amid TL1A concerns. Latest Ratings for STTK Date Firm Action From To Apr 2021 Berenberg Initiates Coverage On Buy Jan 2021 Evercore ISI Group Initiates Coverage On Outperform Nov 2020 Cowen & Co. Initiates Coverage On Outperform View More Analyst Ratings for STTK View the Latest Analyst Ratings read more